OR 2299
Alternative Names: OR-2299Latest Information Update: 30 Apr 2021
At a glance
- Originator OncoResponse
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Natural killer cell modulators; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Apr 2021 OR 2299 is available for licensing as of 08 Apr 2021. https://oncoresponseinc.com/partnering/overview.php
- 08 Apr 2021 Preclinical trials in Cancer in USA (Parenteral), prior to April 2021 (Oncoresponse pipeline, April 2021)
- 08 Apr 2021 OncoResponse plans a phase I trial in Cancer, in the Q4 2021 (OncoResponse pipeline, April 2021)